ALLO-715

Overview

ALLO-1715 is an allogeneic (donor-derived) CAR T cell therapy targeting B-cell maturation antigen (BCMA) that is being developed as a potential novel treatment for multiple myeloma and other BCMA-positive malignancies.

SparkCures ID 339
Developed By Allogene Therapeutics
Generic Name ALLO-715
Treatment Classifications
Treatment Targets

Clinical Trials

Resources